Community-acquired pneumonia associated with Mycoplasma pneumoniae: diagnostic and treatment approaches

Alexander I. Sinopalnikov , Igor E. Tyurin , Igor A. Guchev

For citation:

Abstract

Community-acquired pneumonia (CAP) contributes greatly to the structure of the infectious disease morbidity and mortality rates, especially in people of older age groups and patients suffering from chronic diseases of internal organs. Streptococcus pneumoniae and Haemophilus influenzae represent the most common CAP causative agents that often contribute to rapid disease progression and therefore require early prescription of adequate antimicrobial therapy. According to the clinical guidelines, the first line drugs are beta-lactams and in certain cases “respiratory” fluoroquinolones. After the end of the COVID-19 pandemic, during which anti-epidemic measures limiting transmission of viral and bacterial agents were widely used, growth of the rate of pneumonia associated with Mycoplasma pneumonia was reported in many countries. In most cases, mycoplasmal pneumonia has a mild course and is characterized by favorable prognosis, which, however, does not eliminate severe disease forms. The growing number of cases of mycoplasmal infection resistant to macrolide therapy should also be considered.
Keywords: community-acquired pneumonia caused by Mycoplasma pneumoniae, diagnosis and antimicrobial therapy of mycoplasmal pneumonia.

References

1. Клинические рекомендации. Внебольничная пневмония у взрослых. ID 654_2. Российское респираторное общество, Межрегиональная ассоциация по клинической микробиологии и антимикробной химиотерапии. 2024.

Clinical guidelines. Community-acquired pneumonia in adults. ID 654_2. Russian Respiratory Society, Interregional Association for Clinical Microbiology and Antimicrobial Chemotherapy. 2024 (in Russian).

2. Gupta AB, Flanders SA, Petty LA et al. Inappropriate diagnosis of pneumonia among hospitalized adults. JAMA Internal Med 2024;184(5):548-56.

3. Ishida T, Miyashita N, Nakahama C. Clinical differentiation of atypical pneumonia using Japanese guidelines. Respirology 2007;12(1):

104-10.

4. Riano-Sanchez LF, Alvarez-Moreno CA, Godoy M et al. Multiplex PCR Pneumonia Panel in Critically Ill Patients Did Not Modify Mortality: A Cohort Study. Antibiotics (Basel) 2025;14(3).

5. Rachina SA, Kupryushina OA, Strelkova DA et al. Etiology of community-acquired pneumonia in adults in Russian hospitals after the COVID-19 pandemic: results of a multicenter prospective study. Clin Microbiol Antimicrobial Chemother 2024;26(2):141-7.

6. Jain S, Self WH, Wunderink RG et al. Community-Acquired Pneumonia Requiring Hospitalization among U.S. Adults. N Engl J Med 2015;373(5):415-27.

7. Иванчик Н.В., Козлов С.Н., Рачина С.А. и др. Антибиотикорезистентность возбудителей фатальных внебольничных пневмоний у взрослых. Клиническая микробиология и антимикробная химиотерапия. 2008;10(4):368-80.

Ivanchik N.V., Kozlov S.N., Rachina S.A., et al. Antibiotic resistance of pathogens causing fatal community-acquired pneumonia in adults. Clinical microbiology and antimicrobial chemotherapy. 2008;10(4):368-80 (in Russian).

8. Markussen DL, Kommedal O, Knoop ST et al. Microbial aetiology of community-acquired pneumonia in hospitalised adults: A prospective study utilising comprehensive molecular testing. Int J Infect Dis 2024;(143):107019.

9. Abelenda-Alonso G, Calatayud L, Rombauts A et al. Multiplex real-time PCR in non-invasive respiratory samples to reduce antibiotic use in community-acquired pneumonia: a randomised trial. Nature Communications 2024;15(1).

10. Shoar S, Musher DM. Etiology of community-acquired pneumonia in adults: a systematic review. Pneumonia (Nathan) 2020;(12):11.

11. Gadsby NJ, Russell CD, McHugh MP et al. Comprehensive Molecular Testing for Respiratory Pathogens in Community-Acquired Pneumonia. Clin Infect Dis 2016;62(7):817-23.

12. Bordon J, Slomka M, Gupta R et al. Hospitalization due to community-acquired pneumonia in patients with chronic obstructive pulmonary disease: incidence, epidemiology and outcomes. Clin Microbiol Infect 2020;26(2):220-6.

13. Waldeck F, Kramer TS, Boutin S et al. Re-emergence of Mycoplasma pneumoniae before and after COVID-19 pandemic in Germany. BMC Infect Dis 2025;25(1):318.

14. Gavaud A, Holub M, Asquier-Khati A et al. Mycoplasma pneumoniae infection in adult inpatients during the 2023-24 outbreak in France (MYCADO): a national, retrospective, observational study. Lancet Infect Dis 2025.

15. Garzoni C, Bernasconi E, Zehnder C et al. Unexpected increase of severe Mycoplasma pneumoniae pneumonia in adults in Southern Switzerland. Clin Microbiol Infect 2024;30(7):953-4.

16. Hansen K, Yamba Yamba L, Wasserstrom L et al. Exploring the microbial landscape: uncovering the pathogens associated with community-acquired pneumonia in hospitalized patients. Front Public Health 2023;(11):1258981.

17. Meyer Sauteur PM, Beeton ML, group EtEMs. Mycoplasma pneumoniae: gone forever? Lancet Microbe 2023;4(10):e763.

18. Edelstein IA, Ivanova OV, Romashov OI, Kozlov RS. Course of Lower Respiratory Tract Infection in Young People Treated at the Military Hospital of Smolensk Garrison with Detected Mycoplasma pneumoniae Carrying a Macrolide-Resistant Mutation in 23S rRNA Gene. Pathogens 2023;12(1).

19. Korneenko E, Rog I, Chudinov I et al. Antibiotic resistance and viral co-infection in children diagnosed with pneumonia caused by Mycoplasma pneumoniae admitted to Russian hospitals during October 2023-February 2024. BMC Infect Dis 2025;25(1):363.

20. Lieberman D, Lieberman D, Schlaeffer F, Porath A. Community-acquired pneumonia in old age: a prospective study of 91 patients admitted from home. Age Ageing 1997;26(2):69-75.

21. Orr PH, Peeling RW, Fast M et al. Serological study of responses to selected pathogens causing respiratory tract infection in the institutionalized elderly. Clin Infect Dis 1996;23(6):1240-5.

22. Waites KB, Xiao L, Liu Y et al. Mycoplasma pneumoniae from the Respiratory Tract and Beyond. Clin Microbiol Rev 2017;30(3):747-809.

23. Clyde WA, Jr. Clinical overview of typical Mycoplasma pneumoniae infections. Clin Infect Dis 1993;17(Suppl.1):S32-36.

24. Chambers ST, Town GI, Neill AM et al. Legionella, Chlamydia pneumoniae and Mycoplasma infection in patients admitted to Christchurch Hospital with pneumonia. N Zealand Med J 1999;112(1090):222-4.

25. Kim CK, Chung CY, Kim JS et al. Late abnormal findings on high-resolution computed tomography after Mycoplasma pneumonia. Pediatrics 2000;105(2):372-8.

26. Pereyre S, Goret J, Bebear C. Mycoplasma pneumoniae: Current Knowledge on Macrolide Resistance and Treatment. Front Microbiol 2016;(7):974.

27. Matsumoto M, Nagaoka K, Suzuki M et al. An adult case of severe life-threatening Mycoplasma pneumoniae pneumonia due to a macrolide-resistant strain, Japan: a case report. BMC Infect Dis 2019;19(1):204.

28. Chen B, Pan J, Peng Y et al. Characteristics and risk factors for outcomes in patients with Mycoplasma pneumoniae mono- and coinfections: A multicenter surveillance study in Wuhan, China, 2023. Infect Dis Model 2025.

29. Qu J, Zhang J, Chen Y et al. Aetiology of severe community acquired pneumonia in adults identified by combined detection methods: a multi-centre prospective study in China. Emerg Microbes Infect 2022;11(1):556-66.

30. Lim YK, Kweon OJ, Kim HR et al. Impact of bacterial and viral coinfection in community-acquired pneumonia in adults. Diagnostic Microbiol Infect Dis 2019;94(1):50-4.

31. Nordholm AC, Soborg B, Jokelainen P et al. Mycoplasma pneumoniae epidemic in Denmark, October to December, 2023. Euro Surveill 2024;29(2):2300707.

32. Bolluyt DC, Euser SM, Souverein D et al. Increased incidence of Mycoplasma pneumoniae infections and hospital admissions in the Netherlands, November to December 2023. Euro Surveill 2024;29(4).

33. ESGMAC Maps study group. Global spatiotemporal dynamics of Mycoplasma pneumoniae re-emergence after COVID-19 pandemic restrictions: an epidemiological and transmission modelling study. Lancet Microbe 2025;6(4):101019.

34. Castelan-Martinez OD, Hernandez-Carbajal E, Contreras-Garcia CE et al. [Effectiveness of the outpatient treatment of the community-acquired pneumonia: systematic review and meta-analysis]. Rev Med Inst Mex Seguro Soc 2016;54(1):128-36.

35. Matuz M, Bognar J, Hajdu E et al. Treatment of Community-Acquired Pneumonia in Adults: Analysis of the National Dispensing Database. Basic Clin Pharmacol Toxicol 2015;117(5):330-4.

36. Ye X, Sikirica V, Schein JR et al. Treatment failure rates and health care utilization and costs among patients with community-acquired pneumonia treated with levofloxacin or macrolides in an outpatient setting: a retrospective claims database analysis. Clin Ther 2008;30(2):358-71.

37. Pomilla PV, Brown RB. Outpatient treatment of community-acquired pneumonia in adults. Arch Intern Med 1994;154(16):1793-802.

38. Ewig S, Kolditz M, Pletz M et al. [Management of Adult Community-Acquired Pneumonia and Prevention – Update 2021 – Guideline of the German Respiratory Society (DGP), the Paul-Ehrlich-Society for Chemotherapy (PEG), the German Society for Infectious Diseases (DGI), the German Society of Medical Intensive Care and Emergency Medicine (DGIIN), the German Viological Society (DGV), the Competence Network CAPNETZ, the German College of General Practitioneers and Family Physicians (DEGAM), the German Society for Geriatric Medicine (DGG), the German Palliative Society (DGP), the Austrian Society of Pneumology Society (OGP), the Austrian Society for Infectious and Tropical Diseases (OGIT), the Swiss Respiratory Society (SGP) and the Swiss Society for Infectious Diseases Society (SSI)]. Pneumologie (Stuttgart) 2021;75(9):665-729.

39. Metlay JP, Waterer GW, Long AC et al. Diagnosis and Treatment of Adults with Community-acquired Pneumonia. An Official Clinical Practice Guideline of the American Thoracic Society and Infectious Diseases Society of America. Am J Respir Crit Care Med 2019;200(7):e45-e67.

40. Heffelfinger JD, Dowell SF, Jorgensen JH et al. Management of community-acquired pneumonia in the era of pneumococcal resistance: a report from the Drug-Resistant Streptococcus pneumoniae Therapeutic Working Group. Arch Intern Med 2000;160(10):1399-408.

41. Martin-Loeches I, Torres A, Nagavci B et al. ERS/ESICM/ESCMID/ ALAT guidelines for the management of severe community-acquired pneumonia. Eur Respir J 2023;61(4).

42. Mandell LA, Marrie TJ, Grossman RF et al. Canadian guidelines for the initial management of community-acquired pneumonia: an evidence-based update by the Canadian Infectious Diseases Society and the Canadian Thoracic Society. The Canadian Community-Acquired Pneumonia Working Group. Clin Infect Dis 2000;31(2):383-421.

43. Mandell LA, Bartlett JG, Dowell SF et al. Update of practice guidelines for the management of community-acquired pneumonia in immunocompetent adults. Clin Infect Dis 2003;37(11):1405-33.

44. Summary of the evidence. Pneumonia (community-acquired): antimicrobial prescribing. Guidance. NICE. Available at: https://www.nice.org.uk/guidance/ng138/chapter/Summary-of-the-evidence; accessed: 16.02.2025.

45. Lim WS, Smith DL, Wise MP et al. British Thoracic Society community acquired pneumonia guideline and the NICE pneumonia guideline: how they fit together. Thorax 2015;70(7):698-700.

46. Rodriguez-Leal CM, Gonzalez-Corralejo C, Candel FJ, Salavert M. Medical societies for the 5th edition of Pneumonia D. Candent issues in pneumonia. Reflections from the Fifth Annual Meeting of Spanish Experts 2023. Rev Esp Quimioter 2024;37(3):221-51.

47. Candel FJ, Salavert M, Basaras M et al. Ten Issues for Updating in Community-Acquired Pneumonia: An Expert Review. J Clin Med 2023;12(21).

48. Yanagihara K, Kohno S, Matsusima T. Japanese guidelines for the management of community-acquired pneumonia. Int J Antimicrob Agents 2001;18(Suppl.1):S45-48.

49. Yatera K, Yamasaki K. Management of the Diagnosis and Treatment of Pneumonia in an Aging Society. Intern Med (Tokyo) 2024.

50. Akinosoglou K, Leventogiannis K, Tasouli E et al. Clarithromycin for improved clinical outcomes in community-acquired pneumonia: A subgroup analysis of the ACCESS trial. Int J Antimicrob Agents 2025;65(2):107406.

51. Edelstein IA. Mycoplasma pneumoniae – modern data on the structure, molecular biology and epidemiology of the pathogen. Clin Microbiol Antimicrobial Chemother 2023;25(4):332-49.

52. Feng M, Burgess AC, Cuellar RR et al. Modelling persistent Mycoplasma pneumoniae biofilm infections in a submerged BEAS-2B bronchial epithelial tissue culture model. J Med Microbiol 2021;70(1).

53. De Groot RCA, Zhu H, Hoogenboezem T et al. Mycoplasma pneumoniae Compared to Streptococcus pneumoniae Avoids Induction of Proinflammatory Epithelial Cell Responses despite Robustly Inducing TLR2 Signaling. Infect Immunity 2022;90(8):e0012922.

54. Benedetti F, Curreli S, Zella D. Mycoplasmas-Host Interaction: Mechanisms of Inflammation and Association with Cellular Transformation. Microorganisms 2020;8(9).

55. Li P, Lili Z, Lin L et al. Expression and clinical significance of MUC5AC in airway of children with Mycoplasma pneumoniae pneumonia. J Pract Med = Shiyong Yixue Zazhi 2023;39(20).

56. Kim K, Jung S, Kim M et al. Global Trends in the Proportion of Macrolide-Resistant Mycoplasma pneumoniae Infections: A Systematic Review and Meta-analysis. JAMA Netw Open 2022;5(7):e2220949.

57. Chih-Cheng L, Hsueh CC, Hsu CK et al. Disease burden and macrolide resistance of Mycoplasma pneumoniae infection in adults in the Asia-Pacific region. Int J Antimicrob Agents 2024;64(2):107205.

58. Kuo CY, Tsai WC, Lee HF et al. The epidemiology, clinical characteristics, and macrolide susceptibility of Mycoplasma pneumoniae pneumonia in children in Southern Taiwan, 2019-2020. J Microbiol Immunol Infection = Wei mian yu gan ran za zhi 2022;55(4):611-9.

59. Miyashita N, Ogata M, Fukuda N et al. Macrolide-resistant Mycoplasma pneumoniae infection prevalence increases again in Osaka. Respiratory investigation. 2025;63(4):517-520.

60. Darazam IA, Rabiei MM, Gharehbagh FJ et al. Recent Macrolide Resistance Pattern of Mycoplasma Pneumonia in the World: A Systematic Review and Meta-Analysis. Iranian J Public Health 2025;54(3):530-41.

61. Xie P, Zhang Y, Qin Y et al. Macrolide resistance in Mycoplasma pneumoniae in adult patients. Front Cellular Infect Microbiol 2025;(15):1496521.

62. Wang N, Zhou Y, Zhang H, Liu Y. In vitro activities of acetylmidecamycin and other antimicrobials against human macrolide-resistant Mycoplasma pneumoniae isolates. J Antimicrob Chemother 2020;75(6):1513-7.

63. Voronina EN, Gordukova MA, Turina IE et al. Molecular characterization of Mycoplasma pneumoniae infections in Moscow from 2015 to 2018. Eur J Clin Microbiol Infect Dis 2020;39(2):257-63.

64. Matsvay AD, Bezrukov V, Nikolaeva P et al. Cultivation and molecular characterization of complete genome sequences of M. pneumoniae isolated in Russia. Clin Microbiol Antimicrob Chemother 2024;26(3):274-84.

65. Miyashita N, Akaike H, Teranishi H et al. Macrolide-resistant Mycoplasma pneumoniae pneumonia in adolescents and adults: clinical findings, drug susceptibility, and therapeutic efficacy. Antimicrob Agents Chemother 2013;57(10):5181-5.

66. Yue H, Sheng Q, Wang X et al. A comparison of diagnostic and therapeutic approaches for Mycoplasma pneumoniae pneumonia in children and adults, during the post-COVID-19 pandemic era. Eur J Clin Microbiol Infect Dis 2025.

67. Guchev IA, Yu VL, Sinopalnikov A et al. Management of nonsevere pneumonia in military trainees with the urinary antigen test for Streptococcus pneumoniae: an innovative approach to targeted therapy. Clin Infect Dis 2005;40(11):1608-16.

68. Park S, Oh KC, Kim KS et al. Role of Atypical Pathogens and the Antibiotic Prescription Pattern in Acute Bronchitis: A Multicenter Study in Korea. J Korean Med Sci 2015;30(10):1446-52.

69. Miyashita N, Kawai Y, Kato T et al. Rapid diagnostic method for the identification of Mycoplasma pneumoniae respiratory tract infection. J Infect Chemother 2016;22(5):327-30.

70. Self WH, Courtney DM, McNaughton CD et al. High discordance of chest x-ray and computed tomography for detection of pulmonary opacities in ED patients: implications for diagnosing pneumonia. Am J Emerg Med 2013;31(2):401-5.

71. Ibrahim D, Bizri AR, El Amine MA, Halabi Z. Chest computed tomography and chest X-ray in the diagnosis of community-acquired pneumonia: a retrospective observational study. J Int Med Res 2021;49(8):3000605211039791.

72. Miyashita N, Nakamori Y, Ogata M et al. Clinical Differences between Community-Acquired Mycoplasma pneumoniae Pneumonia and COVID-19 Pneumonia. J Clin Med 2022;11(4).

73. Sui DX, Ma HC, Wang CC et al. Diagnostic significance of HRCT imaging features in adult mycoplasma pneumonia: a retrospective study. Sci Rep 2024;14(1):153.

74. Tanaka H. Correlation between Radiological and Pathological Findings in Patients with Mycoplasma pneumoniae Pneumonia. Front Microbiol 2016;(7):695.

75. Sato H, Okada F, Nakao Y, Asayama Y. A decision tree for predicting the causative pathogens of community-acquired pneumonia from thin-section computed tomography. Jpn J Radiol 2025;43(3):412-21.

76. Miyashita N, Kawai Y, Yamaguchi T et al, Atypical Pathogen Study G. Clinical potential of diagnostic methods for the rapid diagnosis of Mycoplasma pneumoniae pneumonia in adults. Eur J Clin Microbiol Infect Dis 2011;30(3):439-46.

77. Yoon IA, Hong KB, Lee HJ et al. Radiologic findings as a determinant and no effect of macrolide resistance on clinical course of Mycoplasma pneumoniae pneumonia. BMC Infect Dis 2017;17(1):402.

78. Meyer Sauteur PM, Krautter S, Ambroggio L et al. Improved Diagnostics Help to Identify Clinical Features and Biomarkers That Predict Mycoplasma pneumoniae Community-acquired Pneumonia in Children. Clin Infect Dis 2020;71(7):1645-54.

79. Riordan A. In children with respiratory symptoms are Mycoplasma pneumoniae PCR and serology clinically significant? Arch Dis Child Educ Pract Ed 2014;99(4):157.

80. Spuesens EB, Fraaij PL, Visser EG et al. Carriage of Mycoplasma pneumoniae in the upper respiratory tract of symptomatic and asymptomatic children: an observational study. PLoS Med 2013;10(5):e1001444.

81. Meyer Sauteur PM, Seiler M, Truck J et al. Diagnosis of Mycoplasma pneumoniae Pneumonia with Measurement of Specific Antibody-Secreting Cells. Am J Respir Crit Care Med 2019;200(8):1066-9.

82. Carter MJ, Mitchell RM, Meyer Sauteur PM et al. The Antibody-Secreting Cell Response to Infection: Kinetics and Clinical Applications. Front Immunol 2017;(8):630.

83. Watkins-Riedel T, Stanek G, Daxboeck F. Comparison of SeroMP IgA with four other commercial assays for serodiagnosis of Mycoplasma pneumoniae pneumonia. Diagnostic Microbiol Infect Dis 2001;40(1-2):21-5.

84. Ishida T, Hashimoto T, Arita M et al. [Evaluation of community-acquired pneumonia guidelines of Japanese Respiratory Society: differentiation of atypical pneumonia and bacterial pneumonia]. J Jap Respir Soc = Nihon Kokyuki Gakkai zasshi 2002;40(12):929-35.

85. Kozlov RS, Ivanchik NV, Skleenova EY et al. In vitro activity of cefpodoxime against Russian clinical isolates of Haemophilus influenzae, Streptococcus pneumoniae and Streptococcus pyogenes. Clin Microbiol Antimicrobial Chemother 2023;25(4):372-8.

For citation:Sinopalnikov A.I., Tyurin I.E., Guchev I.A. Community-acquired pneumonia associated with Mycoplasma pneumoniae: diagnostic and treatment approaches. Clinical review for general practice. 2025; 6 (11): 43–50 (In Russ.). DOI: 10.47407/kr2025.6.11.00710

All accepted articles publish licensed under a Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) which allows users to read, copy, distribute and make derivative works for non-commercial purposes from the material, as long as the author of the original work is cited properly.

Clinical review for general practice